We are live on ! Find out more
UOC

UBS O'Connor Portfolio holdings

AUM $3.76B
1-Year Est. Return 62.41%
This Fund
S&P 500
This Quarter Est. Return
+8.75%
1 Year Est. Return
+62.41%
3 Year Est. Return
+179.84%
5 Year Est. Return
+371.69%
10 Year Est. Return
+1,534.25%
AUM
$3.69B
AUM Growth
-$542M
Cap. Flow
-$781M
Cap. Flow %
-21.18%
Top 10 Hldgs %
56.86%
Holding
480
New
156
Increased
61
Reduced
86
Closed
113

Top Buys

Rank Stock Value
1
SKX
Skechers
SKX
+$207M
2
BPMC
Blueprint Medicines
BPMC
+$176M
3
WBA
Walgreens Boots Alliance
WBA
+$167M
4
DNB
Dun & Bradstreet
DNB
+$122M
5
INFA
Informatica
INFA
+$93.8M

Top Sells

Rank Stock Value
1
DFS
Discover Financial Services
DFS
+$408M
2
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$408M
3
HES
Hess
HES
+$251M
4
BECN
Beacon Roofing Supply, Inc.
BECN
+$195M
5
BERY
Berry Global Group, Inc.
BERY
+$137M

Sector Composition

Rank Sector Weight
1 Healthcare 19.77%
2 Technology 14.28%
3 Consumer Staples 10.98%
4 Energy 9.87%
5 Consumer Discretionary 9.66%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CACI icon
376
CACI
CACI
$13.8B
– –
-20,950
Closed -$7.69M
CATX icon
377
Perspective Therapeutics
CATX
$357M
– –
-96,060
Closed -$205K
CCCC icon
378
C4 Therapeutics
CCCC
$463M
– –
-39,868
Closed -$63.8K
CCL icon
379
CALL
Carnival Corporation Ltd
CCL
$32.2B
– –
-150,000
Closed -$24K
CCL icon
380
PUT
Carnival Corporation Ltd
CCL
$32.2B
– –
-120,000
Closed -$83.4K
CCRN
381
DELISTED
Cross Country Healthcare
CCRN
– –
-804,764
Closed -$12M
CE icon
382
CALL
Celanese
CE
$4.9B
– –
-70,000
Closed -$40.3K
CGEM icon
383
Cullinan Oncology
CGEM
$1.42B
– –
-32,903
Closed -$249K
CLBR
384
DELISTED
Colombier Acquisition Corp II
CLBR
– –
-150,000
Closed -$1.6M
CLBR.WS
385
DELISTED
Colombier Acquisition Corp. II Warrants, each whole warrant exercisable for one Class A Ordinary Share at an exercise price of $11.50 per share
CLBR.WS
– –
-90,000
Closed -$69.3K
CMC icon
386
Commercial Metals
CMC
$7.77B
– –
-85,020
Closed -$3.91M
CNI icon
387
Canadian National Railway
CNI
$74.6B
– –
-133,975
Closed -$13.1M
CNTB
388
Connect Biopharma Holdings
CNTB
$116M
– –
-268,946
Closed -$148K
CNTX icon
389
Context Therapeutics
CNTX
$33.2M
– –
-67,631
Closed -$41.4K
CRH icon
390
CRH
CRH
$62.7B
– –
-113,520
Closed -$9.99M
CRM icon
391
Salesforce
CRM
$213B
– –
-8,896
Closed -$2.39M
CRVS icon
392
Corvus Pharmaceuticals
CRVS
$1.21B
– –
-20,850
Closed -$66.3K
DADA
393
DELISTED
Dada Nexus
DADA
– –
-618,986
Closed -$1.15M
DFS
394
DELISTED
Discover Financial Services
DFS
– –
-2,389,191
Closed -$408M
DG icon
395
Dollar General
DG
$29.4B
– –
-15,000
Closed -$1.32M
DRUG
396
Bright Minds Biosciences
DRUG
$639M
– –
-5,963
Closed -$215K
DYN icon
397
Dyne Therapeutics
DYN
$4.53B
– –
-21,422
Closed -$224K
EH
398
EHang Holdings
EH
$356M
– –
-10,000
Closed -$209K
ERAS icon
399
Erasca
ERAS
$5.66B
– –
-75,627
Closed -$104K
EVLV icon
400
Evolv Technologies
EVLV
$906M
– –
-430,223
Closed -$1.34M
14 15
16
17 18

Similar funds

FNBT
FineMark National Bank & Trust Fort Myers, Florida $3.2B AUM 18.28% 1-Year Est. Return
ACI
Alpha Cubed Investments Irvine, California $2.92B AUM 31.27% 1-Year Est. Return
RC
RGM Capital Naples, Florida $2.06B AUM 8.49% 1-Year Est. Return
A
AlphaQuest New York $1.79B AUM 10.61% 1-Year Est. Return
CGL
Clarius Group LLC Seattle, Washington $1.75B AUM 19.04% 1-Year Est. Return
CB
Cadence Bank Tupelo, Mississippi $1.71B AUM 16.17% 1-Year Est. Return
JCM
Janney Capital Management Pittsburgh, Pennsylvania $1.59B AUM 23.25% 1-Year Est. Return
MPM
Meritage Portfolio Management Overland Park, Kansas $1.51B AUM 26.61% 1-Year Est. Return

UBS O'Connor's Q2 2025 Portfolio in Review

As of Q2 2025, UBS O'Connor held 480 positions worth $3.69B, down 13% from $4.23B the previous quarter. Its ten largest holdings account for 57% of the portfolio.

UBS O'Connor withdrew a net $781M in Q2 2025, closing 113 positions and reducing 86 holdings. Its most notable exit was Discover Financial Services, an estimated $408M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 20% of assets, up from 17% a quarter earlier, followed by Technology and Consumer Staples.

Against the trend, UBS O'Connor opened a new position in Skechers worth $227M.

  • UBS O'Connor's largest Q2 2025 buy was Skechers: 3,598,177 shares worth $227M.
  • UBS O'Connor added most to Blueprint Medicines in Q2 2025, an estimated $176M increase.
  • UBS O'Connor's biggest Q2 2025 reduction was Hess, cutting an estimated $251M.
  • UBS O'Connor fully exited Discover Financial Services in Q2 2025, selling an estimated $408M.
  • UBS O'Connor's ten largest holdings make up 57% of its $3.69B portfolio in Q2 2025.
  • UBS O'Connor opened 156 new positions and closed 113 in Q2 2025.
  • UBS O'Connor's portfolio value fell 13% quarter-over-quarter to $3.69B.

Based on UBS O'Connor's 13F filing for Q2 2025, filed 14 Aug 2025.